Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to 61.84%.

  • Ironwood Pharmaceuticals' EBITDA Margin rose 338500.0% to 61.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.34%, marking a year-over-year increase of 101200.0%. This contributed to the annual value of 26.5% for FY2024, which is 2400400.0% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' EBITDA Margin is 61.84%, which was up 338500.0% from 53.17% recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' EBITDA Margin registered a high of 376.14% during Q2 2021, and its lowest value of 1014.58% during Q2 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 38.14% (2022), whereas its average is 3.96%.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' EBITDA Margin plummeted by -10527200bps in 2023, and later soared by 10410400bps in 2024.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' EBITDA Margin stood at 35.32% in 2021, then increased by 29bps to 45.59% in 2022, then dropped by -30bps to 31.98% in 2023, then grew by 9bps to 34.78% in 2024, then soared by 78bps to 61.84% in 2025.
  • Its EBITDA Margin was 61.84% in Q3 2025, compared to 53.17% in Q2 2025 and 70.75% in Q1 2025.